sacituzumab govitecan trials

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
sacituzumab govitecan trials	0.97	0.4	1702	55	28
sacituzumab	1.21	0.1	9106	49	11
govitecan	1.15	0.5	3979	59	9
trials	0.85	1	4313	92	6

Keyword	CPC	PCC	Volume	Score
sacituzumab govitecan trials	0.86	0.1	4876	91
sacituzumab govitecan clinical trial	0.2	0.7	5823	49
ascent trial sacituzumab govitecan	1.62	0.4	5343	37
sacituzumab govitecan patient information	0.17	0.3	1761	2
sacituzumab govitecan prescribing information	1.55	0.6	500	31
sacituzumab govitecan fda approval	0.78	1	8416	77
is sacituzumab govitecan chemotherapy	1.13	0.6	1173	25
sacituzumab-govitecan	0.28	0.4	1462	64
sacituzumab govitecan drug class	1.06	0.7	7291	90
sacituzumab govitecan phase i	1.38	0.4	7455	25
sacituzumab govitecan urothelial carcinoma	0.31	0.8	5092	100
sacituzumab govitecan bc cancer	1.74	1	3722	76
is sacituzumab govitecan immunotherapy	1.86	0.4	2936	67
sacituzumab govitecan breast cancer	0.99	0.9	519	81
sacituzumab govitecan fda label	0.91	0.6	2290	69
sacituzumab govitecan mechanism of action	0.08	0.2	9540	83
sacituzumab govitecan breast cancer approval	0.46	1	1273	45
sacituzumab govitecan protocol nhs	0.04	0.7	5218	59
sacituzumab govitecan for bladder cancer	1.44	0.2	6057	94
sacituzumab govitecan lung cancer	0.24	0.6	5488	39
sacituzumab govitecan-hziy	0.41	0.5	1825	64
sacituzumab govitecan fiche patient	0.22	1	5812	72
sacituzumab govitecan plus pembrolizumab	1.54	0.8	5532	54
sacituzumab govitecan j code	1.25	0.1	7953	68
acces precoce sacituzumab govitecan	0.51	0.2	6984	73
sacituzumab govitecan brain metastases	0.11	0.4	6465	41